Despite pricing pressure from domestic rivals, Keytruda could still generate billions of dollars a year in China, Cantor analysts predict
Gilead oncology EVP Riva joins Glenmark spinoff as CEO; Biocon's biosimilar plant dinged by FDA; Shionogi licenses Akili's digital therapeutics.
The FDA has picked apart the process of a Jubilant solid-dose plant in India and criticized it for repeating mistakes.
Lupin has indicated it has received another FDA warning letter as regulatory issues continue to pile up for the Indian drugmaker.
Pfizer is closing a Hospira plant in India, but the FDA still issued a warning letter for a list of serious violations it uncovered last year.
The FDA has approved a new generic of Diovan from India's Alkem to help relieve a shortage of the ubiquitous high blood pressure treatment.
The plant in India where Biocon makes the biosimilars it shares with Mylan was given a clean bill of health by the FDA last year—but not for long.
Fujifilm will buy biologics operations in Denmark from Biogen as the Japanese company continues to beef up its CDMO business.
A third carcinogen was found in sartan drugs; China unveiled final rules for a Nasdaq-style board; Philippines preps to indict Sanofi officials.
Japan’s Nichi-Iko Pharmaceutical and its U.S. operation Sagent Pharmaceuticals have bought a plant in North Carolina from Xellia.